BiO2 Medical Inc. Prophylactic Pulmonary Embolism Protection Hospitalized patients are at the greatest risk for a fatal pulmonary embolism within the first 10 days after admission, but traditional inferior vena cava filters to prevent PEs if anticoagulant therapy is contraindicated and/or ineffective are not typically placed in ...
BiO2 Medical Sponsors: Journal of the Intensive Care Society Supplement Pulmonary Embolism – The Future – Optimizing the Prevention of PE in the Critically Ill Patient
Pulmonary embolism – the future Optimising the prevention of PE in the critically ill patient Venous thromboembolism (VTE) remains a major challenge in the care of critically ill patients. Patients in the intensive care unit (ICU) are at high risk for both deep vein thrombosis (DVT) and pulmonary embolism (PE). PE frequently occurs ...
BiO2 Medical Executes Full Commercialization in the United Kingdom Partnering with United Drug Medical (UDM) as an Exclusive Distributor for the Angel® Catheter
BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, has signed a distribution agreement with Pyramed, a division of United Drug Medical (UDM). This milestone accomplishment grants Pyramed exclusive rights to distribute the Angel® Catheter throughout ...
BiO2 Medical Executes Q4 2013 Commercialization Strategy for the Angel® Catheter, Signing Distribution Partnership Agreements in Key European and Middle Eastern Geographies
BiO2 Medical has achieved Q4 2013 global expansion goals for the Angel® Catheter, a novel Central Venous Catheter (CVC) with a permanently attached retrievable Inferior Vena Cava (IVC) filter to provide Pulmonary Embolism (PE) protection for critically ill patients. The Angel® Catheter is the first ...